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Objectives: FXS is the most common inherited form of intellectual disability and is 
associated with comorbidities that impair functioning and adaptive behavior. This 
study is aimed at evaluating the incremental direct health care costs and resource uti-
lization associated with FXS using administrative health care claims data. MethOds: 
Using the Optum Health Reporting and Insights Employer database covering 1999-
2012, subjects < 65 years old with ≥ 1 FXS diagnosis (ICD-9-CM: 759.83) and ≥ 6 months 
of continuous enrollment prior to the first observed FXS diagnosis were matched 
with up to 5 non-FXS controls using high-dimensional propensity score matching. 
Individuals were followed until the end of continuous enrollment in the health plan. 
All-cause and FXS-related costs and resource utilization stratified by hospitalizations, 
emergency room (ER), outpatient, and home care visits were examined. Results: 
590 FXS individuals (mean[median] age: 25.7[27]; female: 54.1%; employee: 32%) and 
2,950 non-FXS controls (mean[median] age: 25.7[27]; female: 52.1%; employee: 32%) 
were identified. Significant differences were observed between FXS and non-FXS in 
the all-cause per-patient per-year (PPPY) incidence of hospitalizations (0.414 vs. 0.237; 
incidence rate ratio [IRR] [95% CI]: 1.75[1.51-2.02]), outpatient visits (14.345 vs. 9.078; 
IRR: 1.58[1.54-1.62]), and home care visits (1.817 vs. 0.348; IRR: 5.22[4.80-5.69]). Similar 
results were found for FXS-related hospitalizations (0.206 vs. 0.092; IRR: 2.23[1.80-
2.77]), outpatient visits (4.929 vs. 1.976; IRR: 2.49[2.39-2.61]), and home care visits (0.341 
vs. 0.029; IRR: 11.70[9.09-15.06]). FXS subjects were also associated with significantly 
higher PPPY all-cause health care costs (total[SD]: $14,674[47,163] vs. $5,110[18,378]; 
hospitalization: $4,507[18,141] vs. $1,328[10,203]; outpatient: $4,730[12,538] vs. 
$2,394[10,515]; drugs: $2,331[6,226] vs. $844[2,244]; p< .01 for all) and FXS-related costs 
(total: $5,890[16,541] vs. $1,744[10,149]; hospitalization: $2,730[13,628] vs. $788[9,506]; 
outpatient: $1,799[4,243] vs. $555[1,510]; drugs: $1,008[2,999] vs. $197[1,030]; p< .01 for 
all), compared to non-FXS controls. cOnclusiOns: The economic burden associated 
with FXS is significant and underscores the need to improve outcomes of individu-
als with FXS.
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Objectives: Multiple Sclerosis (MS) has significant financial consequences for 
health care systems, individual patients and households, and the society in general. 
This study examines the distribution of MS costs and resource utilisation across cost 
categories and from various perspectives, as MS disability increases. MethOds: A 
total of 214 patients with MS were recruited from a specialised MS outpatient clinic 
in Dublin, Ireland, to participate in an interview-based study on MS-related resource 
consumption and costs. Mean annual direct medical, direct non-medical and indi-
rect costs per patient were calculated, stratified by MS disability: mild (n= 114), 
moderate (n= 72) and severe (n= 27). Results: Participants were 66% female; mean 
(sd) age 47.6(12.75) years; mean (sd) EDSS score 3.6(2.6); 53% relapsing-remitting 
MS. Mean annual direct costs increased as MS disability increased from ~€ 10,000 
in mild disease, more than five fold to ~€ 56,000 in severe MS. Direct costs exceed 
indirect costs in mild and severe MS, driven by costly disease-modifying therapies 
and professional home-help respectively. In contrast, indirect costs dominate in 
moderate MS (~€ 32,000 indirect vs. ~€ 13,000 direct) due primarily to early retire-
ment. Disease-modifying therapies account for 76% of total direct costs in mild MS. 
A total of 74%-96% of all direct costs are borne by the health care payer in Ireland. 
Remaining costs are incurred by patients, their families or other non-health care 
organisations predominantly relating to non-medical resources such as living-aids, 
home-modifications and home-help. cOnclusiOns: MS is associated with high 
levels of health care resource consumption and costs, which increase with disability. 
The majority of direct costs in our study are borne by the health care payer. However 
out-of-pocket spending at the individual patient level and the contribution of other 
organisations can be significant, particularly in severe disease. There is potential 
to significantly reduce the economic burden of MS through interventions which 
prevent progression to severe disability, support independent living at home and 
maintain labour force participation.
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Objectives: To examine the annual resource use and related treatment costs for 
patients with paraplegia in Greece in 2011. MethOds: This was a prospective study, 
which recorded data from all inpatient and outpatient visits to Olympion Hospital, a 
private rehabilitation center in Patras, during 2011. Patient files, which recorded the 
patients’ demographic, clinical and economic/ cost data, were created. Direct costs 
included medical and pharmaceutical costs, lab tests and direct non-medical costs, 
which were retrieved through the Center’s IT system. Indirect cost data consisted 
of the loss of individual and family income and were elicited via face-to-face or tel-
ephone interviews with the patients or their relatives. Each patient participating in 
the study signed an informed consent. Results: A total of 300 patients were treated 
in the rehabilitation center in 2011, of which 36 (12%) suffered from paraplegia. Of 
these, 20 were treated in the inpatient setting and 16 in the outpatient setting. The 
total average annual cost of treating patients with paraplegia was estimated at 
€ 101,228; the average costs of the inpatient and outpatient settings were € 86,699 
(€ 74,296 direct cost + € 12,403 indirect cost) and € 14,529 (€ 9,445 direct cost and € 5,084 
indirect cost) respectively. The mean number of hospitalization days for inpatients 
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Objectives: Multiple sclerosis (MS) is a neurodegenerative disease associated 
with long-term disability and significant economic impact. With the addition 
of new agents for the treatment of MS (e.g. natalizumab), there is a need to 
evaluate the relative value of newer therapies in terms of cost, given health 
care resource constraints in Brazil. This analysis considered just the indication 
for rapidly evolving severe relapsing-remitting multiple sclerosis (RESRRMS) 
patients (≥ 2 disabling relapses per year, and ≥ 1 gadolinium-enhancing lesions 
on brain magnetic resonance imaging or a significant increase in T2 lesion load). 
Brazilian reimbursement guidelines recommend natalizumab only as 3rd line 
treatment for MS. A budget impact analysis (BIA) has been created to analyze 
the impact of introducing natalizumab in RESRRMS treatment in Brazilian Public 
Healthcare System (SUS). MethOds: BIA was based on a Markov model with 
monthly cycles and 5-year time horizon with MS epidemiological data obtained 
from Brazilian public database (DATASUS). The model compared current MS 
treatment options reimbursed by the Brazilian government – interferons-betas, 
glatiramer acetate and natalizumab (3rd line) with an alternative scenario with 
1st line natalizumab. Results: The number of Brazilian patients eligible for 
REHARRMS treatment was estimated to be 1,574, 532 and 110 patients for 1st, 2nd 
and 3rd line treatment, respectively, in the first year. Compared to the current 
scenario, the inclusion of natalizumab in the reimbursement protocol for 1st 
line shows potential savings of USD 729.1K, 524.6K, 360.3K, 200.6K and 83.6K for 
5 consecutive years. cOnclusiOns: The inclusion of natalizumab as RESRRMS 
treatment option is estimated to yield savings of USD 1.9 M in five years for MS 
treatment in SUS.
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Objectives: Budget impact analysis of switching Pramipexole Immediate Release 
(IR) to Pramipexole Extended Release (ER) in treatment of Parkinson’s Disease in 
the Turkish health care setting from a Social Security Institution’s (SSI) perspec-
tive. MethOds: Based upon a literature review demonstrating that, Pramipexole 
ER is similar to Pramipexole IR in efficacy and safety in treatment of Parkinson’s 
Disease (non-inferiority), budget impact analyses were performed using Microsoft 
Excel (2007). Results: The switch from IR to ER was analyzed for the following 
formulations 0.75MG /1.50MG /3.00MG /4.50MG per day and patient. The daily 
pill burden per patient was reduced from 3 to 1 and 6 to 1 for 0,75MG /1,5MG 
/3,0MG and 4,5MG respectively. The total annual treatment cost per patient was 
reduced by 2.91%, 6.25%, 1.74% and 3.30% for 0.75MG, 1.50MG, 3.00MG and 4.50MG 
respectively. cOnclusiOns: The findings of this study indicate that, switching 
Parkinson’s Patients from Pramipexole IR to ER will not result in an additional 
budget impact for the Turkish health care system from a SSI perspective. However, 
further research needs to be conducted in order to explore the potential implica-
tions of compliance benefits and if they can be translated into long-term savings. 
No local effectiveness data was available at the time this analysis was performed. 
Potential benefits in patients’ adherence were not considered.
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Objectives: To evaluate MS-related health care resource utilization and costs 
prior to and after initiating natalizumab in the US. MethOds: A retrospective 
administrative claims analysis was conducted using the Truven Health MarketScan 
Commercial and Medicare supplemental databases to identify adults diagnosed 
with MS (ICD-9-CM 340) who initiated natalizumab between January 1, 2007 and 
December 31, 2010 (first claim is the index date). Patients had ≥ 24 months of 
continuous enrollment (12 months before [pre-period] and 12 months after [post-
period] the index date) and remained on natalizumab for the 12 month post-
period. Patients with and without other disease modifying treatment (DMT) during 
the pre-period were examined. Patient characteristics, MS-related inpatient stays 
and corticosteroid use were described in the pre- and post-periods. Results: The 
1458 patients in this study had a mean age of 45.2 years (standard deviation 10.5) 
and 74% were female. The majority (70.1%) used a DMT during the pre-period. After 
initiating natalizumab, there was a significant reduction in percentage of patients 
with MS-related inpatient stays (7.6% vs. 2.4%, p< 0.001), MS-related inpatient costs 
(median $12,078 vs. $9,784, p< 0.001) and length of stay (7.12 days vs. 6.26 days, 
p= 0.005). Reduction in percentage of patients with MS-related inpatient stays 
and costs were numerically higher for patients without DMTs in the pre-period 
(-6.2% and -$1,496 respectively) compared with those with a DMT in the pre-
period (-4.8% and -$1,262, respectively). Compared to the pre-period, there were 
significant reductions in IV and oral corticosteroid use for natalizumab initiators 
(-60.1% and -52.9%, respectively, p< 0.001 for both). These reductions correspond 
to a mean corticosteroid cost per patient reduction of $101 across all natalizumab 
users (p< 0.001). cOnclusiOns: The initiation of natalizumab was associated with 
significant decreases in MS-related inpatient stays and corticosteroid use with 
corresponding decreases in length of stay and costs among natalizumab users 
with and without DMTs in the prior year.
